首页> Blood advances> Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

导出 LinkOut

翻译打印收藏纠错

第一作者： Maximilian,Stahl

第一单位： Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.;Weill Cornell Medical College, New York, NY; and.

作者： Maximilian,Stahl ^[1] ; Kamal,Menghrajani ^[1] ; Andriy,Derkach ^[2] ; Alexander,Chan ^[3] ; Wenbin,Xiao ^[3] ; Jacob,Glass ^[1] ; Amber C,King ^[4] ; Anthony F,Daniyan ^[1] ; Christopher,Famulare ^[1] ; Bernadette M,Cuello ^[5] ; Troy Z,Horvat ^[4] ; Omar,Abdel-Wahab ^[6] ; Ross L,Levine ^[6] ; Aaron D,Viny ^[7] ; Eytan M,Stein ^[1] ; Sheng F,Cai ^[1] ; Mikhail,Roshal ^[3] ; Martin S,Tallman ^[1] ; Aaron D,Goldberg ^[1]

作者单位： Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.;Weill Cornell Medical College, New York, NY; and. ^[1] Department of Epidemiology and Biostatistics. ^[2] Department of Pathology. ^[3] Department of Pharmacy. ^[4] Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY. ^[5] Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.;Weill Cornell Medical College, New York, NY; and.;Human Oncology and Pathogenesis Program, and.;Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, NY. ^[6] Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.;Human Oncology and Pathogenesis Program, and. ^[7]

医学主题词抗肿瘤联合化疗方案(Antineoplastic Combined Chemotherapy Protocols);人类(Humans);白血病, 髓样, 急性(Leukemia, Myeloid, Acute);回顾性研究(Retrospective Studies);磺胺类(Sulfonamides)

DOI 10.1182/bloodadvances.2020003734

PMID 33687434

发布时间 2025-07-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Blood advances

2021年5卷5期

1552-1564页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览0

点击下载本期目录封面

Blood advances

2021年5卷5期

1552-1564页

检索历史清除

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML.

Blood advances

相似文献

同项目论文

Blood advances

相关期刊

检索历史清除